RxDoctor Payments Data

Eugene Kamemoto, MD

Gastroenterology · Honolulu, HINPI 1821082736

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.1% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 27.2% of the total. Reporting peaked in 2019 at $398 and has fallen 68.1% since, to $127 in 2024. That places this record below the midpoint for gastroenterology clinicians in HI, where the typical reported total is $1,198.

$832in general payments, 2019–2025

Across 27 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$226
  • Pfizer$181
  • Boston Scientific$176
  • Takeda Pharmaceuticals U.S.A., Inc.$167
  • Ironwood Pharmaceuticals, Inc$23
  • Intercept Pharmaceuticals, Inc.$20
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$82499%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$832 in reported general payments places this provider in the 40th percentile of 71 gastroenterology providers in Hawaii.

See all gastroenterology providers in Hawaii

Medicare billing

Part B allowed, 2024
$135,837
Medicare patients
729
Services billed
1,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$108,995
Famotidine1,064$36,257
LinzessLinaclotide22$27,527
Omeprazole585$20,196
Mesalamine DrMesalamine31$16,219
Mesalamine18$9,615
Pantoprazole Sodium169$5,145
Ursodiol14$4,145
CholestyramineCholestyramine (With Sugar)39$3,196
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl160$2,807
Esomeprazole Magnesium32$2,305
Rabeprazole Sodium20$1,060
Vancomycin Hcl12$718
Hydrocortisone21$451
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl18$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$226$27,52722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 71 gastroenterology providers in Hawaii.

Other gastroenterology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →